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Abstract. This study aimed to determine whether manipula-
tion of the microRNA‑200 (miR‑200) family could influence 
colon adenocarcinoma cell behavior. The miR-200 family 
has a significant role in tumor suppression and functions as 
an oncogene. In vitro studies on gain and loss of function 
with small interfering RNA demonstrated that the miR-200 
family could regulate RASSF2 expression. Knockdown of the 
miR-200 family in the HT-29 colon cancer cell line increased 
KRAS expression but decreased signaling in the MAPK/ERK 
signaling pathway through reduced ERK phosphorylation. 
Increased expression of the miR-200 family in the CCD-841 
colon epithelium cell line increased KRAS expression and led 
to increased signaling in the MAPK/ERK signaling pathway 
but increased ERK phosphorylation. Functionally, knockdown 
of the miR-200 family led to decreased cell proliferation in 
the HT-29 cells; therefore, increased miR-200 family expres-
sion could increase cell proliferation in the CCD-841 cell line. 
The present study included a large paired miR array dataset 
(n=632), in which the miR‑200 family was significantly found 
to be increased in colon cancer when compared with normal 
adjacent colon epithelium. In a miR-seq dataset (n=199), the 
study found that miR-200 family expression was increased 
in localized colon cancer compared with metastatic disease. 
Decreased expression was associated with poorer overall 
survival. The miR-200 family directly targeted RASSF2 and 
was inversely correlated with RASSF2 expression (n=199, all 
P<0.001). Despite the well‑defined role of the miR‑200 family 
in tumor suppression, the present findings demonstrated a 
novel function of the miR-200 family in tumor proliferation. 
Introduction
MicroRNAs (miRNAs) play a crucial role in the regulation of 
cell function through specific interactions with their messenger 
RNA (mRNA) counterparts. They are small, naturally occur-
ring, non-protein coding RNA molecules that downregulate 
gene expression and affect subsequent protein expression (1,2). 
miRNAs exhibit a variety of crucial regulatory functions 
related to cell growth, development, and differentiation (3,4). 
When miRNAs are overexpressed in cancer, they may func-
tion as oncogenes or tumor suppressors, depending on their 
target mRNA (5,6).
The miR‑200 family consists of five members: miR‑200a, 
miR-200b, miR-200c, miR-141, and miR-429. The miR-200 
family is involved in cell transformation and tumorigenesis, 
cancer metastasis, tumor growth, angiogenesis, invasion, 
migration, and tumor cell survival in the circulation (intravasa-
tion and extravasation). miR-200 can be a potential diagnostic 
and prognostic tool in patients with cancer (7). Differential 
expression of the miR-200 family is involved in initiation 
and progression of malignant transformation. The miR-200 
family regulates epithelial-to-mesenchymal transition (EMT), 
an important step in tumor progression (8,9). The majority of 
cancer studies on the miR-200 family focus on its role in EMT 
regulation and tumor suppression. However, some authors 
report increased levels of the miR-200 family in various 
cancers, which contradicts the tumor suppressive role of this 
miRNA family (10).
This study focuses on colorectal cancer (CRC), which is 
the third-leading cause of cancer-related deaths in the United 
States. The underlying causes of CRC are complex and hetero-
geneous. Sporadic CRC is the most common presentation of 
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CRC and develops from precursor polyps, namely advanced 
adenomas (11). KRAS mutations have been observed in 
35-45% of colorectal adenocarcinomas (12-14). KRAS acts 
as a molecular on/off switch within the mitogen-activated 
protein kinase (MAPK) pathway, a major regulator of cell 
proliferation (15). This MAPK/ERK pathway is believed to 
be implicated in the pathogenesis, progression, and oncogenic 
behavior of CRC. Kinases within this pathway have the poten-
tial to be used as targets for the treatment of CRC (16).
It has been shown that the miR-200 family directly binds 
Ras association domain family member 2 (RASSF2), a nega-
tive regulator of KRAS (17,18); however, the relationship 
between miR-200 family, RASSF2, KRAS, and subsequent 
activity within the MAPK/ERK pathway in CRC, has not yet 
been fully described.
Our aim was to investigate the role of the miR-200 family 
in relation to MAPK/ERK signaling pathway activity and the 
effect upon cell proliferation mediated via the tumor suppressor 
RASSF2. We sought to determine whether manipulation of the 
miR‑200 family could influence colon adenocarcinoma cell 
behavior and thereby have potential use as a therapeutic target.
Materials and methods
The present study was approved by the University of Louisville 
Institutional Review Board. For human studies, tissue samples 
were acquired from the University of Louisville Surgical 
Biorepository and written informed consent was obtained 
from all patients.
Cell line culture. Human colon cell lines, CCD-841 CoN 
(normal colon epithelium, cat. no. CRL-1790; ATCC®, 
Manassas, VA, USA), HT-29 (colon cancer, cat. no. HTB-38; 
ATCC®), and T-84 (colon cancer, cat. no. CCL-248™; ATCC®) 
were prepared using the manufacturer's instructions. CCD-841 
CoN cells were grown in Eagle's minimum essential medium. 
HT-29 cells were grown in McCoy's 5A. The T84 cell line were 
grown in Dulbecco's minimum essential medium supplemented 
with 15, 10, and 10% fetal bovine serum, respectively, with a 
0.5% mixture of penicillin, streptomycin, amphotericin B, and 
0.5% L-glutamine. Cells were plated at 250,000 cells/well and 
allowed to grow to confluence before being harvested for RNA 
or protein extraction and stored at ‑80˚C. Cell lines were tested 
regularly for mycoplasma and were authenticated using short 
tandem repeat analysis (ATCC®).
miRNA screening. The expression levels of 384 miRNAs were 
examined in the HT-29, T-84, and CCD-841 cell lines using 
TaqMan® low density array (TLDA) human miRNA card A 
following the manufacturer's protocol (Life Technologies, 
Carlsbad, CA, USA (19). RT-qPCR was performed using a 
ViiA™ 7 real‑time PCR system (ThermoFisher Scientific,  Inc., 
Middlesex, MA, USA). Expression levels of each individual 
miRNA were normalized to RNU6 (endogenous internal 
reference gene) using a cycle threshold of 0.1 to calculate 
ΔCq values for analysis using the comparative ΔΔCq method. 
The HT-29 cell line was chosen for further analysis as it was 
the most significantly dysregulated from the T‑84 cell line. 
miRNA expression of the HT-29 cell line was compared to the 
miRNA expression of the CCD-841 CoN cell line.
miRNA single assay confirmation. Validation of significantly 
dysregulated miRNAs identified from screening was performed 
using specific TaqMan® miRNA primers and probes with 
RT-qPCR (Life Technologies, Carlsbad, CA, USA). Nucleic acid 
quantification was performed using a Step‑One Plus RT‑qPCR 
system (Life Technologies). The levels of each individual 
miR-200 family member (hsa-miR-429, cat. no: 4427975/assay 
ID: 001024, hsa-miR-200c, cat. no: 4427975/assay ID: 002300, 
hsa-miR-200b, cat. no: 4427975/assay ID: 002251, hsa-miR-200a 
cat. no: 4,427,975/assay ID: 000502, hsa-miR-141 cat. 
no: 4427975/assay ID: 000463) were normalized to RNU6 (cat. 
no: 4427975/assay ID: 001973) for each cell line using a cycle 
threshold of 0.1 to calculate ΔCq values for analysis using the 
comparative ΔΔCq method (20). All reactions were completed 
in duplicate.
Bioinformatic analysis. Targets of the miR-200 family were 
screened using Ingenuity Pathway Analysis (Qiagen, Hilden 
Germany.) This program uses publicly available datasets and 
the scientific literature to identify dysregulated pathways 
in diseases and potential gaps in molecular signaling. The 
identified molecular interactions were investigated and veri-
fied using mirTarBase (21). The predicted binding between the 
miR-200 family and RASSF2 has previously been experimen-
tally verified using dual‑luciferase reporter assay and Northern 
blotting (22). The results of this study demonstrate the direct 
binding interaction between the miR-200 family and RASSF2.
The Cancer Genome Atlas and microarray datasets. The 
RNA-seq expression data for RASSF2 and microRNA-seq 
expression data for the miR-200 family in patients with 
colon adenocarcinoma was downloaded from cbioportal 
(http://www.cbioportal.org/accessed 10/01/2018). The 
microRNA-seq expression data for the same patients with 
colon adenocarcinoma was downloaded from Firebrowse 
(http://firebrowse.org/ accessed 11/20/18). The associated 
clinical dataset was downloaded from The Cancer Genome 
Atlas (TCGA, https://portal.gdc.cancer.gov/). The GSE115513 
microarray normalized dataset was downloaded from Gene 
Expression Omnibus. The paired tumor and normal adjacent 
tissue datasets were extracted.
Reverse transcription (RT) and quantitative real‑time poly‑
merase chain reaction (RT‑qPCR). Isolation of total RNA 
from cell lysates was performed using the Ambion® miRVana 
miRNA isolation kit (Life Technologies). Quantitation of total 
RNA quantity and quality was determined using a Nanodrop 
2000 spectrophotometer (ThermoFisher Scientific,, Inc.). 
Complementary DNA (cDNA) was generated from 10 ng total 
RNA samples using the TaqMan® miRNA reverse transcription 
kit (Life Technologies). qPCR was performed using 1.33 µl of 
cDNA and TaqMan® microRNA assays (Life Technologies). 
Reactions were run in duplicate.
mRNA quantification. For mRNA quantification, total 
RNA was converted to cDNA using a high-capacity 
cDNA reverse transcription kit (Life Technologies) with 
random nucleotide primers. Specific TaqMan® probes 
for RASSF2 (cat. no: 4331182/Hs00248129_m1) and 18S 
(cat. no: 4331182/Hs03928990_g1) (endogenous internal 
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reference gene) were used during RT-qPCR. All reactions 
were completed in duplicate. Nucleic acid quantification was 
performed using a Step-One Plus RT-qPCR system (Life 
Technologies). The expression levels of RASSF2 mRNA were 
normalized to 18S using a cycle threshold of 0.1 to calculate 
ΔCq values for analysis using the comparative ΔCq method.
miRNA transfection. Each cell line was transfected with each 
individual member of the miR-200 family. Scrambled oligonu-
cleotides served as a negative control using mirVana™ miRNA 
mimics (for CCD-841 CoN) and antagomirs (for HT-29) (Life 
Technologies). Once plated, cells were allowed a 24-h acclima-
tion period to adhere to the plate prior to transfection. After 24 h, 
when cells were 60‑80% confluent in each well, they were trans-
fected using Lipofectamine® RNAiMAX transfection reagent 
(Life Technologies), according to the manufacturer's protocol.
Immunoblotting. Cells were lysed using radio immune-precip-
itation assay (RIPA) buffer and the protein concentration 
determined using the bicinchoninic acid (BCA) assay. Forty 
micrograms of total protein from each cell lysate was separated 
by NuPAGE® MOPS SDS and transferred on to a nitrocellu-
lose membrane. The primary antibodies used were RASSF2 
EPR6621 (1:1,000; Abcam) and β-actin (1:10,000; Cell 
Signaling Technology). Secondary antibodies used were 
HRP-conjugated goat anti-rabbit and horse anti-mouse IgG 
(1:1,000; Cell Signaling Technology). The membrane was incu-
bated in equal parts of enhanced chemiluminescence (ECL) 
reagents A and B for 5 min in the dark to detect the target 
protein, and then developed and imaged using a ChemiDoc 
MP imager (BioRad, Hercules, CA, USA).
Enzyme‑linked immunosorbent assay. Cells were seeded in 
6-well plates (250,000 cells/well) and transfected as previ-
ously described. After 24 h, cell sample lysates were harvested 
with cell lysis mix and protein concentration determined 
using the BCA assay. Fifty microliters of cell lysate and 50 µl 
of pre-prepared antibody cocktail mix were added into an 
InstantOne™ ELISA 96 well plate (Affymetrix, Santa Clara, 
CA, USA), according to the manufacturer's protocol. Total and 
phosphorylated ERK1/2 levels were measured by reading the 
absorbance of the samples using the SPECTRAmax® PLUS 
384 microplate spectrophotometer at a wavelength of 450 nm.
Cell proliferation assay. HT-29 and CCD-841 CoN cells were 
plated in duplicate at a concentration of 100,000 cells/ml and 
50,000 cells/ml in individual wells in 12-well plates, respectively. 
After 24 h, cells were serum-starved in 0.5% FBS for 2 h before 
replacement of normal growth medium and then transfected 
with miRNA mimics and antagomirs as previously described. 
Transfection was stopped after 24 h, and cells were trypsinized. 
A 10 µl sample from each well was inserted into a dual chamber 
counting slide (Bio-Rad), and the cell number was measured daily 
for 5 days using an automated cell counter (TC20™, Bio-Rad).
Human tissue. Fresh frozen tissue samples of colon cancer 
and normal adjacent colon epithelial tissue, which was taken 
at least 10 cm from the primary lesion from five patients diag-
nosed with stage III adenocarcinoma were obtained from the 
University of Louisville surgical biorepository.
Laser capture microdissection. Tissue serial sections were cut 
at 7-µm thickness, mounted, and stained using the Histogene™ 
LCM frozen section staining kit. One slide stained with 
hematoxylin and eosin per sample was used as reference. 
Colon cancer and normal adjacent colon epithelial tissue 
were identified and laser captured using the ArcturusXT™ 
laser capture microdissection system. RNA was extracted and 
isolated using the Arcturus® PicoPure® frozen RNA isolation 
kit. RT and RT-qPCR for the miR-200 family and RASSF2 
was performed. Protein was extracted and RASSF2 measured 
via western blot analysis as previously described.
Statistical analysis. For each cell line and transfected miRNA, 
samples were prepared in replicates of five unless otherwise 
stated. Cell culture samples were grown from new freezes and 
transfected at the same passage to maintain a true sample size 
of five. All reactions were run in duplicate, and averages of the 
duplicates were used for analysis. The chi-squared test or Fischer 
exact test, where appropriate, were used to compare categorical 
variables. The independent Student's t-test or Mann-Whitney U 
test was used to compare continuous non-paired variables. The 
difference in paired continuous data was done with the Wilcoxon 
signed-rank test. For tests with multiple comparisons, a repeated 
measures analysis of variance with post hoc Bonferroni correc-
tion was performed. The difference in overall and recurrence-free 
survival were assessed by Kaplan-Meier survival analysis and 
the log rank test. Univariable and multivariable Cox regression 
analyses were done to identify risk factors for a reduced overall 
survival. Correlation between mRNA and miRNA expression 
was analyzed with Spearman Rank correlation test. Statistical 
analysis was performed using the Statistical Package for the 
Social Sciences (SPSS) v25.0 (IBM Corp, Armonk, NY, USA). 
Graphs were prepared using GraphPad Prism v6.01 (GraphPad 
Software, Inc., La Jolla, CA, USA). P<0.05 was considered to 
indicate a statistically significant difference. Data are presented 
as mean ± standard deviation (SD).
Results
miR‑200 family expression is increased in colorectal cancer 
and is increased in localized cancer compared with metastatic 
cancer
In vitro studies. To verify that the miR-200 family was upregu-
lated in an in vitro model, we screened for the expression of 
384 miRNAs, using TLDA miRNA arrays cards in the human 
colon adenocarcinoma cell lines HT-29 and T-84 compared 
with a normal colon epithelial (CCD-841 CoN) cell line (Fig. 1). 
The miR‑200 family was the most significantly upregulated. 
As the HT-29 cell line showed the greatest differential expres-
sion of the miR-200 family as compared with the normal colon 
epithelial cell line and is known to demonstrate an epithelial 
phenotype (23), it was chosen for further study. These data 
were confirmed on single assay analysis. Comparison between 
the HT-29 and CCD-841 CoN cell lines showed elevated levels 
of miR-200a, miR-200b, miR-200c, miR-141, and miR-429 in 
HT-29 samples (P<0.0001; Fig. 2A). miR-200 family expres-
sion in cells was increased or suppressed by transfection with 
individual miRNA mimics (CCD-841 CoN) (P<0.001) or 
antagomirs (HT-29) [miR-200b P<0.01, miR-200c P<0.001, 
(Fig. 2B and C)].
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Studies using data from human biorepositories. Using the 
paired microRNA microarray GSE115513 dataset (n=632), all 
members of the miR-200 family were increased in colorectal 
cancer compared with paired normal adjacent colon epithelium 
(all P<0.001; Fig. 3). As the miR-200 family is known to have 
a role in cancer progression, the miR-200 family expression 
was examined between localized (stage I and II) and metastatic 
(stage III and IV) colon adenocarcinoma microRNA-seq dataset 
derived from TCGA [(n=229); Fig. 3]. Using the median expres-
sion as a cut-off, miR-200a (P=0.006), miR-200c (P<0.001), 
and miR-141 (P=0.003) were all significantly increased in 
localized cancer compared with metastatic cancer. Additionally, 
miR‑200b (P=0.06) and miR‑429 (P=0.08) had a significant trend 
towards increased expression in localized cancer compared with 
metastatic cancer. As expected, low miR-200a (log-rank=0.02), 
mirR-200b (log-rank=0.05), and miR-200c (log-rank=0.03) 
expression were significantly associated with worse overall 
survival. miR-429 (P=0.61) and miR-141 (P=0.30) were not 
associated with worse overall survival (Fig. 3). Low cancer tissue 
miR-200a, low miR-200b, and low miR-200c expression were 
significantly associated with advanced stage disease (Table I). 
On univariable and multivariable analysis, low tumor miR-200a, 
low miR‑200b, and low miR‑200c were all significant predictors 
of shorter overall survival (Table II). Individual multivariable 
Cox regression models were used due to the expected significant 
collinearity between members of the miR-200 family.
miR‑200 family targets the tumor suppressor RASSF2. Utilizing 
microarray screening data, Ingenuity Pathway Analysis (Qiagen, 
Hilden, Germany) identified relevant miRNAs and associated 
pathways. The MAPK/ERK signaling pathway was the pathway 
most closely linked to the colon cancer cell line screening data. 
All members of the miR‑200 family were significantly enriched 
within this pathway (Fig. S1). miRTarBase identified all five 
miR200 family miRNAs (miR-200a, miR-200b, miR-200c, 
miR-141, miR-429) to target the same gene, RASSF2. The 
miR-200 family previously has been demonstrated to directly 
bind RASSF2 using dual-luciferase reporter assay and Northern 
blotting (22). Expression of all members of the miR-200 family 
was significantly inversely correlated with that of RASSF2 
using TCGA dataset (Fig. 4). Decreased RASSF2 expression 
was associated with a trend towards a worse recurrence-free 
survival (P=0.058; Fig. 5).
miR‑200 family expression can regulate RASSF2 mRNA 
expression. RASSF2 mRNA expression was significantly 
decreased in HT-29 cells as compared with CCD-841 CoN 
(fold regulation -6282, P<0.001). Knock down of the miR-200 
family in HT-29 cells led to increased RASSF2 mRNA expres-
sion in the HT‑29 cell line significantly for miR‑429 with a 
fold change of 3.82 (P<0.001; Fig. 6A). Overexpression of the 
miR-200 family in CCD-841 CoN cells led to a decreased 
RASSF2 mRNA expression. miR-200a and miR-200b mimics 
significantly downregulated RASSF2 mRNA (fold regulation= 
-1.45, P=0.01, and fold regulation= -1.74, P<0.001; Fig. 6B).
miR200 family expression can regulate RASSF2 protein 
expression. The change in RNA expression was verified by 
examining RASSF2 protein expression. RASSF2 protein was 
present in CCD-841 CoN cells, whereas no RASSF2 protein 
was detected in the HT-29 cell line (Fig. 7A and B). Transfection 
with miR-200 family member mimics led to a decreased trend 
in RASSF2 protein expression in the CCD-841 CoN cell line. 
RASSF2 protein levels were significantly lower in CCD‑841 
CoN cells when transfected with miR-200a, miR-200b, 
miR-429 mimics (P<0.05; Fig. 7C). Increased expression of 
RASSF2 protein expression was observed in the HT-29 cell 
line with transfection of miR-141 and miR-429 antagomirs 
(P<0.05; Fig. 7D).
miR‑200 family can regulate activity in the MAPK/ERK 
pathway. Transfection with miR-200 family mimics led to an 
increased trend in KRAS protein expression in the CCD-841 
CoN cells. There were significant increases observed 
with miR-200a, miR-141, and miR-429 (P<0.05; Fig. 8A). 
Transfection with miR-200 family antagomirs led to KRAS 
protein in the HT‑29 cells, and there were significant increases 
observed with miR-200a and miR-200c knockdown (P<0.05; 
Fig. 8B). The normalized expression of KRAS in the HT-29 
cells was 10-fold lower than that of the CCD-841 cells, which 
suggests there was low endogenous expression of KRAS. 
Subsequent activity within the MAPK pathway was measured 
by ERK phosphorylation compared with total ERK1/2 levels. 
There was an increased ratio of phosphorylated-to-total ERK 
1/2 with transfection of miR-200 family mimics in the CCD-841 
cell line (all P<0.01; Fig. 9A). There was a decreased trend in 
the ratio of phosphorylated-to-total ERK1/2 in the HT-29 cell 
line with transfection of miR-200 family antagomirs. There was 
a significant decrease in the ratio of phosphorylated‑to‑total 
ERK1/2 with transfection of miR-200a, miR-200b, and miR-141 
antagomirs (P<0.05; Fig. 9B). These results indicate that the 
miR-200 family can regulate MAPK/ERK pathway activation, 
in part, through KRAS regulation.
miR‑200 family expression can regulate cell prolifera‑
tion. As the MAPK/ERK pathway is a major regulator of 
Figure 1. Waterfall plot of the significantly dysregulated miRs in colon cancer 
cell lines HT-29 and T-84 as compared to the normal colon epithelial cell line 
(CCD-841). miR200 family is highlighted in yelow. miR, microRNA.
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cellular growth, cell proliferation was measured to analyze 
the functional effect of MAPK/ERK pathway regulation by 
the miR-200 family. Transfection with miR-200a, miR-200c, 
and miR-141 mimics led to increased cell proliferation in 
CCD-841 cells (P<0.05; Fig. 9C). Transfection with miR-200 
antagomirs led to decreased cell proliferation in HT-29 cells 
(all P<0.001; Fig. 9D).
Laser capture microdissection of colon cancer tissue for 
miR‑200 family, RASSF2 mRNA, and RASSF2 protein expres‑
sion. A laser capture microdissection system was used to 
selectively dissect paired cancer tissue and normal epithelium 
from patients with stage III colon adenocarcinoma (Fig. 10A). 
There was downregulation of miR-200a (P=0.047), miR-200b 
(P=0.119), miR-141 (P=0.007), and miR-429 (P=0.027), with 
no difference in miR-200c (P=0.589) in colon cancer tissue 
samples compared with normal adjacent epithelium (Fig. 10B). 
These results reflect the data seen in the previous sequencing 
datasets, where the miR-200 family was downregulated in 
metastatic disease. There was a 2.7-fold downregulation of 
RASSF2 mRNA in the cancer tissue compared with colon 
epithelium (P=0.021; Fig. 10C), and a 6-fold downregulation 
of RASSF2 protein in colon cancer tissue relative to normal 
adjacent epithelium (P=0.092; Fig. 10D).
Discussion
This study describes the role of the miR-200 family in the 
regulation of RASSF2 and the subsequent downstream effect 
upon the MAPK/ERK signaling pathway. All members of the 
miR‑200 family were significantly increased in colon cancer 
tissue compared with paired normal adjacent colon epithelium. 
Interestingly, there was a progressive decrease in miR-200 
family expression in metastatic colon cancer compared with 
localized cancer. The significance of the miR‑200 family in 
colon cancer was further highlighted in a screening miRNA 
array, where it was the most upregulated group of miRNA 
compared with normal colon cells. Pathway analysis software 
and a previous study identified that the miR‑200 family directly 
binds RASSF2 (22). We further demonstrated this by showing 
Figure 2. Baseline miR‑200 family expression and expression post transfection with miR‑200 mimics and antagomirs. (A) Significant upregulation of all 
members of the miR‑200 family in the HT‑29 cell line vs. the CCD‑841 cell line. (B) Significant upregulation of all of the miR‑200 family compared to 
scramble following transfection with individual miR‑200 family mimics in the CCD‑841 cell line. (C) Significant downregulation of miR‑200b and miR‑200c 
following transfection with antagomirs as compared with scramble in the HT-29 cell line. ***P<0.0001 vs. CCD-841; ††P<0.01 and †††P<0.001 vs. scramble. 
miR, microRNA.
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Figure 3. (A-C) miR-200a is increased in cancer tissue compared with normal adjacent epithelium (P<0.001). miR-200a expression is decreased in advanced 
stage (stage III or IV) compared with localized disease (stage I or II, P=0.006.) Low expression of miR-200a is associated with worse overall survival 
(log-rank=0.02). (D-F) miR-200b is increased in cancer tissue compared to normal adjacent epithelium (P<0.001). miR-200b expression is decreased 
in advanced stage (stage III or IV) compared to localized disease (stage I or II) (P=0.06). Low expression of miR-200b is associated with worse overall 
survival (log-rank=0.05). (G-I) miR-200c is increased in cancer tissue compared to normal adjacent epithelium (P<0.001). miR-200c expression is decreased 
in advanced stage (stage III or IV) compared to localized disease (stage I or II, P<0.001). Low expression of miR-200c is associated with worse overall 
survival (log-rank=0.03). (J-L) miR-141 is increased in cancer tissue compared to normal adjacent epithelium (P<0.001). miR-141 expression is decreased 
in advanced stage (stage III or IV) compared to localized disease (stage I or II, P=0.003). No difference in the overall survival between high and low 
miR-141 (log-rank=0.61). (M-O) miR-429 is increased in cancer tissue compared to normal adjacent epithelium (P<0.001). miR-429 expression is decreased 
in advanced stage (stage III or IV) compared to localized disease (stage I or II, P=0.08). No difference in the overall survival between high and low miR-429 
(log-rank=0.30). miR, microRNA.
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a significant inverse correlation between all members of the 
miR-200 family and RASSF2. Transfection with miR-200 
family mimics, and antagomirs could regulate cell prolifera-
tion, in part, by directly regulating RASSF2 expression and 
subsequently increasing MAPK/ERK pathway signaling 
through KRAS.
Although miR-200 family knockdown led to an increased 
trend in RASSF2 expression and induced activation of the 
MAPK/ERK signaling pathway, it increased KRAS expres-
sion in the HT-29 cell line. This discrepancy can be explained, 
as the miR-200 family have a number of different target 
molecules, and KRAS has a number of upstream regulators. 
Table I. Clinicopathological variables for patients with colon adenocarcinoma in the Cancer Genome Atlas dataset.
Variables Total (n=199) Localized disease (n=114) Metastatic disease (n=85)
Age, years (median, IQR) 66 (56-75) 69 (58-77) 64 (52-73)
Sex
  Male 112 (56) 67 (59) 45 (53)
  Female 87 (44) 47 (41) 40 (47)
Race
  Caucasian 162 (85) 93 (86) 69 (83)
  African-American 29 (15) 15 (14) 14 (17)
Anatomical location
  Cecum  54 (29) 29 (27) 25 (31)
  Ascending colon  38 (2) 26 (24) 12 (15)
  Hepatic flexure 13 (7) 6 (6) 7 (9)
  Transverse colon  14 (7) 8 (7) 6 (7)
  Splenic flexure 4 (2) 3 (3) 1 (1)
  Descending colon 10 (5) 5 (5) 5 (6)
  Sigmoid colon 56 (30) 30 (28) 26 (32)
Lymphatic invasion
  Yes 48 (27) 7 (7) 41 (55)
  No 130 (73) 96 (93) 34 (45)
Venous invasion
  Yes 38 (22) 7 (7) 44 (59)
  No 137 (78) 93 (93) 31 (41)
Perineural invasion
  Yes 36 (29) 15 (21) 21 (39)
  No 88 (71) 55 (79) 33 (61)
miR-200a
  Low 100 (50) 49 (43) 51 (60)
  High   99 (50) 65 (57) 34 (40)
miR-200b
  Low 100 (50) 51 (45) 49 (58)
  High   99 (50) 63 (55) 36 (42)
miR-200c
  Low 100 (50) 45 (40) 55 (65)
  High    99 (50) 69 (60) 30 (35)
miR-141
  Low 100 (50) 47 (41) 53 (62)
  High    99 (50) 67 (59) 32 (38)
miR-429
  Low 100 (50) 53 (47) 47 (55)
  High   99 (50) 61 (54) 38 (45)
Categorical data expressed as N (%). Continuous data compared using Mann-Whitney U test. Categorical data compared using χ2 test. Boldface 
shows significant difference. IQR, Interquartile Range.
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Knockdown of the miR-200 family can induce ZEB1 expres-
sion, which can, in turn, induce KRAS expression (24). 
Previous studies have demonstrated an inverse relationship 
between miR-200 family members and KRAS expression 
in certain cancers (24,25). In a number of breast cancer cell 
lines, miR-200c expression was inversely proportional to 
KRAS expression (25). Despite these results, the miR-200 
family knockdown decreased ERK phosphorylation in the 
MAPK/ERK signaling cascade.
This study did not make a direct comparison between 
the cell lines, but there was an approximately 10-fold 
increase in the expression KRAS in the CCD-841 cells 
compared with the HT-29 cells. This is likely suggestive of 
either low endogenous KRAS expression in the HT-29 cell 
line or the miR-200 family is mediating its effect, in part, 
through another signaling cascade (26). All members of the 
miR-200 family also could be decreasing cellular prolifera-
tion, which was found to be mediated through MAPK/ERK 
signaling.
An apparent discrepancy in the miR-200 family expres-
sion between the cell line comparison data and the human 
tissue data can be explained by the microarray and TCGA 
data. The miR-200 family expression was increased in cancer 
tissue compared with paired normal adjacent tissue, but the 
data from the miRNA-seq indicated that there was decreased 
expression in metastatic cancer compared with localized 
Figure 4. Correlation of miR-200 family expression with RASSF2 expression in the colon adenocarcinoma TCGA dataset. (A-E) The miR-200 family is 
significantly inversely correlated with RASSF2 expression (n=199, P<0.001). miR, microRNA.
Figure 5. Reduced expression of RASSF2 was associated a trend towards worse recurrence-free survival (log-rank=0.058).
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tissue. This process of differential miR-200 family expression 
has been noted by other authors and is suggestive of the EMT 
process (27). The intra-tumoral microRNA expression varies 
widely in colon adenocarcinoma, which may also influence 
the results of expression assays (9,28). While laser capture 
microdissection is an appropriate methodology for the specific 
Figure 6. Expression of RASSF2 mRNA following transfection with miR-200 mimics and with miR-200 antagomirs. (A) Increased trend in the expression 
of RASSF2 in the HT-29 cell line following transfection with miR-200 antagomirs as compared with scramble (A-). *P=0.01. (B) Decreased trend in the 
expression of RASSF2 mRNA in the CCD-841 cell line following transfection with miR-200 mimics as compared with scramble (M-). *P=0.01 and **P<0.001 
vs. scramble. miR, microRNA.
Figure 7. Baseline RASSF2 protein expression and following transfection miR-200 mimics or antagomirs. (A) RASSF2 protein is expressed in the CCD-841 
cell line at baseline. (B) There is no RASSF2 protein expression in the HT-29 cell line at baseline. (C) Following transfection with miR-200 mimics, there is 
reduced expression of RASSF2 protein compared to scramble with miR-200a, miR-200b, and miR-429 (*P<0.05 vs. scramble). Histograms are representative 
of n=5 experimental repeats for all transfections. Representative blots demonstrating significant decrease in RASSF2 expression following transfection with 
miR-429 mimics compared to scramble. (D) Following transfection with miR-200a and miR-200c antagomirs, there was an increased trend in RASSF2 
protein expression. RASSF2 expression was significantly increased with miR‑141 and miR‑429 antagomir transfection (*P<0.05 vs. scramble). Histograms 
are representative of n=5 experimental repeats for all transfections. Representative blots demonstrating significant increase in RASSF2 expression following 
transfection with miR-429 antagomirs compared to scramble. miR, microRNA.
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identification of tumoral microRNA expression, it is chal-
lenging to have appropriate tissue for both RNA and protein 
analysis.
The miR-200 family could regulate the MAPK/ERK 
signaling pathway in the current study, which is a known major 
regulator of cell proliferation (29). There is a large body of 
evidence that suggests that this pathway is involved in the patho-
genesis, progression, and oncogenic CRC behavior (16,30). 
KRAS was indirectly regulated by the miR-200 family in 
this study and was a key upstream signaling molecule in this 
pathway (31). However, oncogenic mutations in KRAS are 
found in approximately 40% of colorectal cancers, and there 
Figure 8. Expression of KRAS protein following transfection of miR-200 mimics or antagomirs. (A) Increased KRAS protein expression in the CCD-841 cell 
line following transfection of miR-200a, miR-141, and miR-429 mimics compared to scramble (M-). (B) Increased expression of KRAS in the HT-29 following 
transfection of miR-200a and miR-200c antagomirs compared with scramble (A-). *P<0.05 vs. scramble. miR, microRNA.
Figure 9. MAPK/ERK pathway activity and cell proliferation. (A) Significant upregulation of the ratio of phosphorylated to total ERK1/2 compared to nega-
tive control (M-) indicating increased MAPK pathway activation following transfection with all miR-200 family mimics in the CCD-841 CoN (normal colon 
epithelial) cell line. **P<0.002 vs. scramble. (B) Significant decrease in the ratio of ERK1/2 compared to negative control (A‑) indicating decreased MAPK 
pathway activation following transfection with miR-200a, miR-200b, and miR-141 antagomirs in HT-29 (stage III colon cancer) cell line. *P<0.05 vs. scramble. 
(C) There is significantly increased proliferation in the CCD‑841 CoN cell line following transfection with miR‑200a, miR‑200c, and miR‑141 mimics. 
*P<0.05 vs. scramble. (D) There is significantly decreased cellular proliferation following transfection with antagomirs of all members of the miR‑200 family. 
***P<0.001 vs. scramble. miR, microRNA.
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are a number of upstream regulator molecules apart from the 
miR-200 family (32). Despite this, the interaction between 
the miR-200 family and KRAS signaling has been observed 
in different cancers. In an enrichment pathway analysis, the 
MAPK and EGFR signaling pathways contained the greatest 
number of targets for miR-200c in a murine breast cancer 
model (33). Furthermore, miR-200c suppressed prolifera-
tion in both wild-type and mutated KRAS breast cancer cell 
lines (25). Interestingly, in a mutant KRAS lung adenocar-
cinoma model, overexpression of miR-200a, miR-200b, and 
miR-429 inhibited tumor growth and metastasis through 
alternative pathway signaling (34). High Ras activity is accom-
panied by increased ERK1/2 activity (35).
A significant number of studies examining the miR‑200 
family in CRC focus on EMT. It has been hypothesized that 
loss of miR-200 family expression in tumors may facilitate 
EMT, thereby enhancing tumor migration and invasion (26,36). 
This has been translated into a number of clinical studies in 
which low tissue expression of the miR-200 family members is 
associated with worse overall survival (37,38), cancer‑specific 
survival (38,39), and non-response to chemotherapy (38). The 
converse proliferative role of the miR-200 family in CRC has 
been demonstrated in other studies, whereby increased miR-200 
expression is associated with proliferation and decreased 
expression is associated with invasion and migration (27).
The function of the miR-200 family can vary between 
types of cancer. Increased expression of miR-200a and 
miR-200c induce a mesenchymal and more aggressive 
phenotype in melanoma, despite the expected suppression of 
ZEB1 (40). An alternative signaling pathway though myris-
toylated alanine-rich protein kinase C substrate (MARCKS) 
was suggested, which produced a similar phenotype to that 
of the miR-200 family. Interestingly, Dykxhoorn et al (41) 
reported increased expression of the miR-200 family in a 
murine breast cancer cell line, which metastasized to the liver 
and lung, echoing the suggestion that the miR-200 family may 
have alternative roles in different cancer types.
This exploratory study summarizes the novel role of the 
miR-200 family in regulating the MAPK/ERK signaling 
pathway and subsequent cellular proliferation. Although the 
miR-200 family have shared seed sequences, they may have 
individual functions that account for the differences observed 
in these data. Further study is needed to explore the regulatory 
functions of the miR-200 family in the MAPK/ERK signaling 
pathway.
In conclusion, the miR‑200 family is significantly increased 
in colon cancer and directly binds RASSF2 in the MAPK/ERK 
signaling pathway. Reduced expression of miR-200 family 
members leads to decreased MAPK/ERK pathway activity 
and a reduction in cell proliferation in HT‑29 cells. These find-
ings suggest that the miR-200 family may have an oncogenic 
role in colon cancer and may therefore provide opportunities 
for targeted therapies.
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